United Health Products, Inc. 8-K

What Happened

• On July 7, 2026 United Health Products, Inc. (UEEC) announced an agreement with NAMSA, a global MedTech contract research organization, under which NAMSA will serve as the regulatory sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze in connection with UHP’s FDA Premarket Approval (PMA) application. The company filed the announcement on Form 8‑K on July 10, 2026 and attached the press release as Exhibit 99.1.
• The filing refers investors to the risk factors disclosed in UHP’s Annual Report on Form 10‑K for the year ended December 31, 2025 regarding risks related to the PMA application.

Key Details

• Press release date: July 7, 2026; Form 8‑K filed July 10, 2026.
• Partner: NAMSA, an established global MedTech contract research organization, will act as regulatory sponsor for the clinical study.
• Product: CelluSTAT Hemostatic Gauze — study is intended to support UHP’s FDA PMA application.
• Exhibit: Press release included as Exhibit 99.1 to the 8‑K.

Why It Matters

• This is a regulatory-development update: naming a CRO/regulatory sponsor is a step toward conducting the clinical work needed for an FDA PMA, which is typically required for market clearance of certain medical devices.
• For investors, the item signals progress on UHP’s path toward potential regulatory approval and commercialization of CelluSTAT, but it is not an approval or a guarantee of future revenue. The company explicitly points investors to its existing PMA‑related risk disclosures in the 2025 Form 10‑K.